TLX Financials: Results, Ratios & Statements | Telix Pharmaceuticals

TLX

Telix Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimizing damage to healthy tissues.

Short position

short percentage10.62%

reported shorts36.1M

shares on issue340.330M

Telix Pharmaceuticals (ASX:TLX) has 10.62% of its shares on issue reported as short positions as of 5 Oct 2026, or about 36,146,864 shares. Over the past 30 days that figure has risen 0.21 percentage points, and over 90 days it has fallen 1.24 percentage points. Its highest recorded short interest was 16.51% in April 2026. TLX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 31 Dec 2025 (FY25) vs FY24, figures in USD, the reporting currency · Company filing, 20 Feb 2026

Revenue: 803.8M (source: ASX (Markit))vs 516.6M (source: ASX (Markit)) (FY24); ASX (Markit), as at 29 Sep 2026
NPAT: −7.1M (source: ASX (Markit))vs 33.7M (source: ASX (Markit)) (FY24); ASX (Markit), as at 29 Sep 2026
EPS (basic): −0.021 (source: Company filing (extracted))vs 0.76 (source: Company filing (extracted)) (FY24); Company filing (extracted), as at 29 Sep 2026

Rev YoY: +55.6%FY
EPS YoY: n/aFY

ASX (Markit)
Company filing (extracted)

Summary of 2025 Full Year Results Announcement, 20 Feb 2026

Telix Pharmaceuticals (TLX) reported strong FY2025 results, with revenue soaring 56% to US$803.8 million, though the company recorded a non-material loss before tax of US$5.3 million. No dividend was declared. Looking ahead, Telix forecasts Group Revenue for FY2026 to be between US$950 million and US$970 million.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 31 Dec 2025 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: n/a
Net margin: −0.9%
FCF margin: n/a
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net debt (excl. leases): n/a
Net debt / EBITDA: n/a
Current ratio: n/a
Interest cover: n/a
Cash dividends paid / net profit: n/a
Market cap: n/a (listed unit is not one ordinary share)
P/E: n/a (listed unit is not one ordinary share)
P/B: n/a (listed unit is not one ordinary share)

Ratios use the reporting currency (USD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.

Financial statements

Figures in USD, the reporting currency; Yahoo Finance unless marked

TLX income, newest period first, figures in USD
Line item	FY25	FY24	FY23	FY22
Revenue	803.8M (source: ASX (Markit))	516.6M (source: ASX (Markit))	333.0M (source: ASX (Markit))	111.0M (source: ASX (Markit))
NPAT	−7.1M (source: ASX (Markit))	33.7M (source: ASX (Markit))	4.2M (source: ASX (Markit))	−72.2M (source: ASX (Markit))
EPS basic	−0.021 (source: Company filing (extracted))	0.76 (source: Company filing (extracted))	n/a	n/a
Shares	338.8M	334.7M	323.7M	316.3M

ASX (Markit)
Company filing (extracted)

Financial reports

The company's own filings, newest first

Showing 10 of 89 reports